Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma

This study tests an experimental CAR-T cell therapy called U29 Injection—a treatment where your own immune cells are taken out, genetically modified in a lab to better recognize and attack cancer cells, and then returned to your body—for patients with a type of blood cancer called lymphoma that carries a protein called CD30 on its surface and has come back or stopped responding to treatment. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with Hodgkin lymphoma, anaplastic large cell lymphoma, or another CD30-positive lymphoma that has relapsed or not responded to treatment - You have failed at least two prior lines of chemotherapy (or a stem cell transplant) - You are in reasonable physical condition (ECOG 0–3) - Your heart, liver, kidneys, and blood counts meet minimum function requirements **You may NOT be eligible if...** - You have had prior CAR-T or gene-modified cell therapy - You have active uncontrolled infection, HIV, active hepatitis B or C, or syphilis - You have had a recent heart attack, severe heart failure, or dangerous heart rhythm problems - You have an active autoimmune disease or active graft-versus-host disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.